Wedoany.com Report-Dec.9, Mirum Pharmaceuticals announced on Monday that it has agreed to acquire Bluejay Therapeutics in a transaction valued at up to $820 million, gaining global rights to brelovitug, a late-stage monoclonal antibody for chronic hepatitis D.

Chronic hepatitis D, a severe liver infection that occurs only in individuals with hepatitis B, affects approximately 230,000 patients in the United States and Europe and currently has no approved treatments.

The acquisition includes an upfront payment of $250 million in cash and $370 million in Mirum stock, with an additional $200 million possible through future sales milestones. Mirum estimates peak annual global revenue for brelovitug could reach at least $750 million, serving 2,000 to 3,000 patients.

"This is another savvy transaction by Mirum bringing in a derisked asset with excellent strategic fit at a low upfront cost," said Citizens Bank analyst Jonathan Wolleben.

In a Phase 2 trial, 48 weeks of brelovitug treatment reduced hepatitis D viral levels in all participants, while up to 82% of patients achieved normalized liver enzyme levels. Mirum has secured $200 million in financing through a private placement to support continued development and future commercialization.

The ongoing Phase 3 study is expected to deliver top-line results in the second half of 2026. Subject to positive outcomes, Mirum intends to file for U.S. regulatory approval and target a commercial launch in 2027.

The transaction is scheduled to close in the first quarter of 2026.

Hepatitis D is recognized as the most aggressive form of viral hepatitis and carries a high risk of rapid progression to cirrhosis and liver cancer. According to Mirum, nearly half of diagnosed patients face liver-related mortality within ten years.

The acquisition strengthens Mirum's pipeline in rare liver diseases and positions the company to address a significant unmet medical need in this patient population. Mirum shares traded 3% lower in Monday morning trading, with the company's market capitalization standing at approximately $3.52 billion.